1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond), 2021, 41(10): 1037-1048.
|
3. |
Aschele C, Glynne-Jones R. Selecting a TNT schedule in locally advanced rectal cancer: can we predict who actually benefits? Cancers (Basel), 2023, 15(9): 2567.
|
4. |
Hong YS, Kim SY, Lee JS, et al. Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol, 2019, 37(33): 3111-3123.
|
5. |
Roselló S, Papaccio F, Roda D, et al. The role of chemotherapy in localized and locally advanced rectal cancer: a systematic revision. Cancer Treat Rev, 2018, 63: 156-171.
|
6. |
Erlandsson J, Lörinc E, Ahlberg M, et al. Tumour regression after radiotherapy for rectal cancer - results from the randomised Stockholm Ⅲ trial. Radiother Oncol, 2019, 135: 178-186.
|
7. |
Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm Ⅲ): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol, 2017, 18(3): 336-346.
|
8. |
Radu C, Berglund A, Påhlman L, et al. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol, 2008, 87(3): 343-349.
|
9. |
Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol, 2021, 22(1): 29-42.
|
10. |
Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol, 2021, 22(5): 702-715.
|
11. |
Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2. 2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2022, 20(10): 1139-1167.
|
12. |
Papaccio F, Roselló S, Huerta M, et al. Neoadjuvant chemotherapy in locally advanced rectal cancer. Cancers (Basel), 2020, 12(12): 3611. doi: 10.3390/cancers12123611.
|
13. |
Michael-Robinson JM, Biemer-Hüttmann A, Purdie DM, et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut, 2001, 48(3): 360-366.
|
14. |
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357(6349): 409-413.
|
15. |
Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med, 2022, 386(25): 2363-2376.
|
16. |
Chen G, Jin Y, Guan WL, et al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol, 2023, 8(5): 422-431.
|
17. |
Yu JH, Liao LE, Xiao BY, et al. Long-term outcomes of dMMR/MSI-H rectal cancer treated with anti-PD-1-based immunotherapy as curative-intent treatment. J Natl Compr Canc Netw, 2024, 22(3): e237096.
|
18. |
Bando H, Tsukada Y, Inamori K, et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. Clin Cancer Res, 2022, 28(6): 1136-1146.
|
19. |
Wang Y, Shen L, Wan J, et al. Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: a new era for anal preservation. Front Immunol, 2022, 13: 1067036.
|
20. |
Zhang T, Tao K, Lin Z, et al. LBA25 neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase Ⅲ trial (UNION). Ann Oncol, 2023, 34 (SUPPLEMENT 2): S1266-S1267.
|
21. |
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res, 2014, 74(19): 5458-5468.
|
22. |
Brix N, Tiefenthaller A, Anders H, et al. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev, 2017, 280(1): 249-279.
|
23. |
Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med, 2012, 366(10): 925-931.
|
24. |
Schrag D, Shi Q, Weiser MR, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med, 2023, 389(4): 322-334.
|
25. |
Schrag D, Shi Q, Weiser MR, et al. PROSPECT: a randomized phase Ⅲ trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048). J Clin Oncol, 2023, 41(17_suppl): LBA2. doi: 10.1200/JCO.2023.41.17_suppl.LBA2.
|
26. |
van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet, 2018, 391(10139): 2537-2545.
|
27. |
Glynne-Jones R, Wallace M, Livingstone JI, et al. Complete clinical response after preoperative chemoradiation in rectal cancer: is a “wait and see” policy justified? Dis Colon Rectum, 2008, 51(1): 10-19, 19-20.
|
28. |
中国直肠癌新辅助治疗后等待观察数据库研究协作组, 中国医师协会外科医师分会中国医师协会肛肠医师分会, 中华医学会外科学分会结直肠外科学组, 等. 直肠癌新辅助治疗后等待观察策略专家共识 (2020版). 中华胃肠外科杂志, 2020, 23(1): 1-9.
|
29. |
Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2. 2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2018, 16(7): 874-901.
|
30. |
André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med, 2020, 383(23): 2207-2218.
|
31. |
Andre T, Elez E, Cutsem E V, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study. J Clin Oncol, 2024, 42(3_suppl): LBA768. doi: 10.1200/JCO.2024.42.3_suppl.LBA768.
|
32. |
Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004, 116(6): 855-867.
|
33. |
Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med, 2014, 371(17): 1609-1618.
|
34. |
Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase Ⅲ BEACON colorectal cancer study. J Clin Oncol, 2019, 37(17): 1460-1469.
|
35. |
Van Cutsem E, Taieb J, Yaeger R, et al. ANCHOR CRC: results from a single-arm, phase Ⅱ study of encorafenib plus binimetinib and cetuximab in previously untreated BRAFV600E-mutant metastatic colorectal cancer. J Clin Oncol, 2023, 41(14): 2628-2637.
|
36. |
Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov, 2011, 1(6): 508-523.
|
37. |
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol, 2016, 17(6): 738-746.
|
38. |
Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021, 19(3): 329-359.
|
39. |
Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol, 2021, 22(6): 779-789.
|
40. |
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 2008, 359(17): 1757-1765.
|
41. |
Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med, 2020, 383(13): 1207-1217.
|
42. |
Xu RH, Xu Y, Yan D, et al. 550O safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): a phase Ⅱ study. Ann Oncol, 2023, 34: S410-S411.
|
43. |
Dienstmann R, Connor K, Byrne AT, et al. Precision therapy in RAS mutant colorectal cancer. Gastroenterology, 2020, 158(4): 806-811.
|
44. |
Zhou C, Li W, Song Z, et al. LBA33 A first-in-human phase Ⅰ study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation. Ann Oncol, 2023, 34: S1273.
|
45. |
Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage Ⅱ colon cancer. N Engl J Med, 2022, 386(24): 2261-2272.
|
46. |
Yukami H, Nakamura Y, Mishima S, et al. Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: updated analysis from GALAXY study in the CIRCULATE-JAPAN. J Clin Oncol, 2024, 42(3_suppl): 6.
|
47. |
Lonardi S, Pietrantonio F, Tarazona Llavero N, et al. LBA28 the PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage Ⅲ and high-risk stage Ⅱ colon cancer patients. Ann Oncol, 2023, 34: S1268-S1269.
|
48. |
van Rees JM, Wullaert L, Grüter AAJ, et al. Circulating tumour DNA as biomarker for rectal cancer: a systematic review and meta-analyses. Front Oncol, 2023, 13: 1083285. doi: 10.3389/fonc.2023.1083285.
|